RE: Will29 Apr 2019 13:32
Traumakine had a lot of confidence behind it before the Results of the INTEREST study where released.
It's results from phase 2 trials where substantially positive with Faron gearing towards manufacturing of at least 120.000 doses to begin.
Corticosteroids are believed to be the reason for the failure of the INTEREST/MARUISHI phase 3 trial study, so results of the YODA study could see Traumakine at least back on a more positive track.